Home » Topics » BioWorld Science

BioWorld Science
RSS

Peptidomimetic TMPRSS2 inhibitor shows prophylactic and therapeutic activity against SARS-CoV-2 VOCs

April 7, 2022

T cell-intrinsic AR activity drives IFN-gamma suppression and immunotherapy resistance

April 7, 2022

Harbour BioMed and AstraZeneca enter global outlicense agreement for HBM-7022

April 7, 2022

HitGen and Uppthera extend their PROTAC collaboration

April 7, 2022

Alternate approach could enable earlier detection, intervention, in Alzheimer's

April 7, 2022

Discovery of noncovalent peptidomimetic proteasome inhibitors for the treatment of MM

April 7, 2022

NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in models of HF

April 7, 2022

BETR-001 shows antidepressant activity in preclinical models

April 7, 2022

FDA clears IND for BiOneCure's anti-Trop-2 ADC, BIO-106

April 7, 2022

Novel series of glucosylceramide synthase inhibitors presented for treating Parkinson's disease

April 7, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...